A new form of spinal cord stimulation (SCS) therapy called BurstDR gained FDA approval today, adding to the growing number of options in the field of neuromodulation.
Its manufacturer, St. Jude Medical, said the new technology provides superior outcomes over traditional SCS therapy.
Last week, National Pain Report wrote about another type of spinal cord stimulation therapy called the Senza HF10, which, too, was shown to provide better outcomes than traditional SCS therapy.
“As a physician, reducing the physical sensation of pain experienced by my patients is only part of my job; my ultimate goal is to help patients overcome both the physical pain and the suffering associated with their pain,” said Dr. Timothy R. Deer, president and chief executive officer of The Center for Pain Relief in Charleston, West Virginia.
“Now, with BurstDR stimulation, St. Jude Medical has armed physicians with a new therapy option that can reduce patients’ pain and suffering, reduce paresthesia and help us offer our patients a more complete pain management option,” Dr. Deer added.
BurstDR stimulation utilizes intermittent “burst” pulses of electrical current designed to mimic the body’s natural nerve impulse patterns. The technology was evaluated within the SUNBURST study, a prospective, randomized multicenter study which concluded it offered superior pain relief over traditional SCS and that the therapy was preferred by most patients over traditional SCS therapy.
“I am very excited that patients across the United States will now have access to BurstDR stimulation, which has enjoyed strong success across other global markets,” said Prof. De Ridder, from the University of Otago in Dunedin, New Zealand. “When I developed BurstDR stimulation my goal was to introduce an entirely new therapy option, and one that was rooted in the natural way in which the human body responds to and combats the sensation of pain.”
“Chronic pain is one of the most costly epidemic diseases facing health care systems worldwide, and one of the most challenging for physicians to manage due to the complexity of the condition and the differences in each patient’s clinical case,” said Allen W. Burton, M.D., medical director of neuromodulation and vice president of medical affairs at St. Jude Medical. “With FDA approval of BurstDR stimulation, we are empowering physicians with a new therapy option in their fight against widespread chronic pain, and our goal is to continue to improve patient outcomes and get more patients the pain relief they deserve.”